AI assistant
BIOLIFE SOLUTIONS INC — Director's Dealing 2021
Apr 22, 2021
32106_dirs_2021-04-21_794ed50c-a6d7-4dc3-9baa-c153d8aeb5d1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2021-04-19
Reporting Person: Mathew Aby J. (Exec VP & Chief Scientific Off)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-19 | Common Stock | M | 10000 | $1.64 | Acquired | 220679 | Direct |
| 2021-04-19 | Common Stock | S | 10000 | $32.62 | Disposed | 210679 | Direct |
| 2021-04-21 | Common Stock | M | 10000 | $1.64 | Acquired | 220679 | Direct |
| 2021-04-21 | Common Stock | S | 10000 | $32.26 | Disposed | 210679 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-19 | Employee Stock Option | $1.64 | M | 10000 | Disposed | 2021-12-20 | Common Stock (10000) | Direct |
| 2021-04-21 | Employee Stock Option | $1.64 | M | 10000 | Disposed | 2021-12-20 | Common Stock (10000) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 12, 2020.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.45 to $33.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.44 to $32.87, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: On December 20, 2016, the reporting person was granted an option to purchase 197,707 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019.